SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bonk refers to a series of comic-style memes in which meme characters such as Doge and Cheems get hit on the head with bats, hammers and other heavy objects, accompanied by the “Bonk” sound effect and clipart. The original image that spawned the meme depicts a Shiba Inu, named Copper. Bonk brings this humor on-chain, transforming the classic meme into a tokenized digital movement powered by community and culture.

Copper Inu

Copper Inu ($COPPER) is trending amid community discussions about its chart patterns and potential for a breakout, particularly in relation to other tokens like $SOL and $BTC. Some users are pointing to its name as indicative of strength, while others express concerns about potential scams.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending due to its upcoming listing on Kraken, generating excitement about increased accessibility and potential price movement. The community is actively discussing staking strategies and accumulating more tokens in anticipation of further exchange listings and long-term gains. Some users also highlight recent institutional investments and positive on-chain data as bullish signals.

Recall is a decentralized skill market for AI where communities fund, rank, and discover the AI solutions they need. Instead of corporations pushing one-size-fits-all AI, Recall flips the dynamic—communities signal demand, developers compete to deliver, and performance determines visibility.

Recall

RECALL CRYPTO is trending due to its recent ICO, with community members actively discussing its potential and current price action. High volume and new highs are fueling interest, though some caution against potential risks associated with new cryptocurrencies. The community is also comparing RECALL to other cryptocurrencies and exploring its potential within the broader crypto market.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending amidst mixed sentiment, with some users expressing frustration and others anticipating a potential uptrend. Community members are actively discussing trading strategies, staking, and the impact of broader market trends on CRO's performance, while also referencing the meme coin $CAW.

Duke Energy Corp. engages in the distribution of natural gas and energy-related services. It operates through the following segments: Electric Utilities and Infrastructure, Gas Utilities and Infrastructure, and Other. The Electric Utilities and Infrastructure segment conducts operations in regulated electric utilities in the Carolinas, Florida and the Midwest. The Gas Utilities and Infrastructure segment focuses on Piedmont, natural gas local distribution companies in Ohio and Kentucky, and natural gas storage and midstream pipeline investments. The Other segment includes interest expense on holding company debt, unallocated corporate costs, and Bison which is a wholly owned captive insurance company. The company was founded on April 30, 1904 and is headquartered in Charlotte, NC.

Duke Energy Corp.

Duke Energy is trending due to a mix of factors, including analyst upgrades and a focus on the company's ability to capitalize on increased power demand from AI data centers. The community is discussing the utility's stable dividend yield, strategic investments in grid modernization and renewable energy, and its role as a defensive stock in a shaky market. Some analysts have increased their price targets, while others point to potential risks related to debt levels and the transition to cleaner energy.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding is trending amid community discussions around its financial strategies, particularly the recent Bitcoin exchange for Semnur shares and investments in Datavault AI, leaving some investors wary. Concerns are rising about potential shareholder dilution and whether these moves will truly benefit the company's core business and Semdexa's progress. The stock's volatility and high short interest are also fueling speculation about a potential short squeeze.

Vale SA engages in the production and exportation of iron ore, pellets, manganese, and iron alloys. It operates through the following segments: Iron Solutions, Energy Transition Materials, Coal and Others. The Iron Solutions segment includes the production and extraction of iron ore, iron ore pellets, manganese, other ferrous products, and logistic services. The Energy Transition Materials segment involves the production and extraction of nickel and its by-products. The Coal segment consists of the production and extraction of metallurgical and thermal coal and its logistic services. Others includes the revenues and cost of other products, services, research and development, investments in joint ventures and associates of other business. The company was founded on June 1, 1942 and is headquartered in Rio de Janeiro, Brazil.

Vale S.A. - ADR

Vale S.A.

Vale is trending as investors discuss portfolio allocations and potential risk-defined entries, with some noting quiet buy-side interest and improving breadth. Community members are also reacting to recent ratings from analysts, while keeping an eye on iron ore futures and overall sector sentiment. Chatter also includes discussion around production and potential impacts of global trade.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is gaining traction as traders discuss its low float and potential for a short squeeze, with comparisons being drawn to other Hong Kong-based stocks that have recently experienced significant gains. Community members are highlighting the company's regained NASDAQ compliance and a substantial contract exceeding its market capitalization as potential catalysts. The high cost to borrow is also fueling speculation about a potential squeeze.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around this Solana-based meme coin, emphasizing its community-driven nature and long-term commitment with some holders staying strong for over a year. Conversations revolve around the playful "What's UpDog?" meme and promoting community engagement across various social media platforms to drive broader awareness.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as community members discuss its potential for growth and speculate about upcoming catalysts, including attending a show in Japan and the Dubai airshow. Some investors are frustrated with a perceived lack of communication from the CEO and are urging action, while others highlight the company's progress toward FAA certification and potential for military applications. Bullish sentiment remains, with some traders pointing to technical patterns and potential breakout opportunities for the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?

Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Taysha Gene Therapies ended at their highest level in over three years on Thursday after a wave of bullish analyst upgrades followed the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy designation for its Rett syndrome gene therapy candidate, TSHA-102.The stock soared 53.5% on Thursday, extending gains by another 2% in after-hours trading.Baird raised its price target on Taysha to $12 from $7 and reiterated an 'Outperform' rating. Analyst Jack Allen said the firm is “encouraged” that Taysha reached alignment with the FDA on the 15-patient pivotal study for TSHA-102, calling the breakthrough therapy designation “another encouraging sign” for the company’s regulatory and clinical progress.H.C. Wainwright said Taysha has added roughly $1.2 billion to its valuation since receiving Breakthrough Therapy designation and aligning with the FDA on a six-month interim Biologics License Application (BLA) filing plan.&nbsp;The firm noted that while the accelerated pathway appears faster “on paper,” Rett specialists it surveyed said the six-month interim analysis was “directionally useful but insufficient on its own to be considered definitive for projecting patient outcomes.”&nbsp;The analysts added that Taysha’s pathway “looks faster on paper, but may not translate into a true lead.” In comparison, the firm said Neurogene, whose FDA-cleared 12-month design “mitigates the risk of approvability,” looks “deeply undervalued.” H.C. Wainwright reiterated its Buy rating and $45 price target on Neurogene, citing its durability focus and caregiver appeal.Needham analyst Gil Blum also raised the price target on Taysha to $10 from $8, keeping a 'Buy' rating. Blum told investors that the FDA’s feedback on Taysha’s registrational study design “checked off a wishlist of features,” including the agency’s willingness to allow for a six-month interim filing. The analyst said these developments “derisk” the TSHA-102 program and position it “well ahead of NGNE-401.”The FDA’s Breakthrough Therapy designation was based on data from 12 patients in an early-to mid-stage trial of TSHA-102 and allows for an expedited review process.&nbsp;Taysha has finalized alignment with the agency on the design of its registrational study, which will test a single intrathecal administration of high-dose TSHA-102 in 15 female patients aged 6 to under 22 years. The company plans to begin enrollment in the fourth quarter of 2025.On Stocktwits, retail sentiment for Taysha was ‘extremely bullish’ amid a 34,800% surge in 24-hour message volume.One retail trader said they expect institutional investors to accumulate Taysha shares around the $5 mark, predicting a quick move toward $6.&nbsp;<stembedurl>https://stocktwits.com/warren5677/message/630844528</stembedurl>Another user said they had exited their position at $4.85, citing the company’s high debt levels and booking an 8% profit.<stembedurl>https://stocktwits.com/intrader/message/630837982</stembedurl><a href="https://stocktwits.com/symbol/TSHA">Taysha’s stock</a> has nearly tripled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Taysha’s stock (TSHA) has nearly tripled so far in 2025. (Photo credit: Getty Images)

Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals

Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy.

Equity

Shares of Taysha Gene Therapies, Inc. (TSHA) rallied 49% by Thursday morning after the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its gene therapy TSHA-102 for the treatment of Rett syndrome.Rett syndrome is a rare genetic neurological and developmental disorder that affects the way the brain develops. The disorder, which primarily occurs in females, is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities, and shortened life expectancy.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-fda-breakthrough-therapy">According</a> to Taysha, there are currently no approved disease-modifying therapies that treat the genetic root cause of the disease, which affects between 15,000 and 20,000 patients in the U.S., the EU, and the U.K.The FDA on Thursday granted Taysha’s TSHA-102 Breakthrough Therapy designation. It is intended to expedite the development and regulatory review of an investigational therapy intended to treat a serious condition. The designation follows the agency’s review of available clinical data from the 12 patients treated in a part of its early-to mid-stage trials.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TSHA">TSHA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:573/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_11_39_41_AM_png_8ca9f60f70.webp" alt="TSHA's Sentiment Meter and Message Volume as of 11:39 a.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="573" height="63"><figcaption>TSHA's Sentiment Meter and Message Volume as of 11:39 a.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>Taysha also said on Thursday that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102. The company is now on track to begin patient enrollment in the trial in the fourth quarter of 2025. In the trial, a single intrathecal administration of high-dose TSHA-102 will be evaluated in 15 females between the ages of six and below 22 years with Rett syndrome.Following the news, Needham analyst Gil Blum raised the firm's price target on Taysha Gene Therapies to $10 from $8 while keeping a ‘Buy’ rating on the shares. Needham views the developments as "derisking" for TSHA-102, putting the program well ahead of Neurogene’s gene therapy NGN-401, which is also being evaluated for Rett syndrome.TSHA stock has risen 174% this year and by about 131% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail buzz around Taysha Gene Therapies Inc surged Tuesday after the company released new clinical results from its TSHA-102 trial for Rett syndrome.Taysha Gene Therapies shares dipped 0.2% to close at $2.78 on Tuesday, before gaining 0.7% to $2.8 in after-hours trading.During its Reveal Phase 1/2 trials, the company presented recent cohort data for TSHA-102, which administered high and low doses to adolescent,&nbsp;adult, and pediatric patients&nbsp;through lumbar intrathecal delivery.Caregiver-reported improvements in developmental milestones supported Taysha’s alignment with the U.S. Food and Drug Administration (FDA) on the primary endpoint for the pivotal Part B trial of TSHA-102.Previously released preclinical data demonstrated broad biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions in non-human primates.Taysha will present these findings in three oral presentations and a poster session at the 2025 International Rett Syndrome Foundation (IRSF) Scientific Meeting in Boston, June 9-11.Canaccord Genuity raised its price target on Taysha shares to $11 from $9, while maintaining a ‘Buy’ rating, citing positive longer-term low-dose follow-up and initial high-dose data disclosed by the company.&nbsp;The research firm also increased its assigned probability of success (POS) for TSHA-102 to 75% from 50%.Canaccord’s updated model also factored in the recently announced approximately $200 million offering via a combination of shares and prefunded warrants.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that it is unusual for a stock to increase during an offering, welcoming Taysha as an exception.&nbsp;<stembedurl>https://stocktwits.com/KING_OF_BIO/message/616691905</stembedurl>Another user highlighted that all price targets for Taysha have been raised.<stembedurl>https://stocktwits.com/strategicmind/message/616553737</stembedurl>The stock has risen 50.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program. 

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Taysha Gene Therapies Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

TSHA
Taysha Gene Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TSHA News

TSHATaysha Gene Therapies Inc